Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial
Authors:
Open Access
- 1 May 2016
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 7, 278-286
Abstract
No abstract availableKeywords
Funding Information
- Aeras
- FDA
- Bill and Melinda Gates Foundation
- Aeras
- FDA (5U18FD004012)
- Bill and Melinda Gates Foundation (OPP1066660)
This publication has 30 references indexed in Scilit:
- Nonclinical Development of BCG Replacement Vaccine CandidatesVaccines, 2013
- Anti–IFN-γ autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of latent varicella-zoster virus infectionBlood, 2013
- Merck Ad5/HIV induces broad innate immune activation that predicts CD8 + T-cell responses but is attenuated by preexisting Ad5 immunityProceedings of the National Academy of Sciences, 2012
- Adult-Onset Immunodeficiency in Thailand and TaiwanNew England Journal of Medicine, 2012
- Varicella zoster virus (VZV) infects and establishes latency in enteric neuronsJournal of NeuroVirology, 2011
- Antagonistic crosstalk between type I and II interferons and increased host susceptibility to bacterial infectionsVirulence, 2010
- An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosisNature, 2010
- A New Recombinant Bacille Calmette‐Guérin Vaccine Safely Induces Significantly Enhanced Tuberculosis‐Specific Immunity in Human VolunteersThe Journal of Infectious Diseases, 2008
- Investigation of the Relationships between Immune‐Mediated Inhibition of Mycobacterial Growth and Other Potential Surrogate Markers of ProtectiveMycobacterium tuberculosisImmunityThe Journal of Infectious Diseases, 2002
- Bactericidal Activity in Whole Blood as a Potential Surrogate Marker of Immunity after Vaccination against TuberculosisClinical and Vaccine Immunology, 2002